BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Özdinler PH. Expanded access: opening doors to personalized medicine for rare disease patients and patients with neurodegenerative diseases. FEBS J 2021;288:1457-61. [PMID: 32805742 DOI: 10.1111/febs.15529] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Genç B, Gautam M, Helmold BR, Koçak N, Günay A, Goshu GM, Silverman RB, Hande Ozdinler P. NU-9 improves health of hSOD1G93A mouse upper motor neurons in vitro, especially in combination with riluzole or edaravone. Sci Rep 2022;12. [DOI: 10.1038/s41598-022-09332-4] [Reference Citation Analysis]
2 Kamusheva M, Milushewa P. Rare disease patients’ needs: an up-to-date analysis and future directions. PHAR 2021;68:763-70. [DOI: 10.3897/pharmacia.68.e73240] [Reference Citation Analysis]
3 Kong M, Zhou T, Xiang B. Expression of the axon guidance factor Slit2 and its receptor Robo1 in patients with Hirschsprung disease: An observational study. Medicine (Baltimore) 2021;100:e26981. [PMID: 34414975 DOI: 10.1097/MD.0000000000026981] [Reference Citation Analysis]
4 Genç B, Gautam M, Gözütok Ö, Dervishi I, Sanchez S, Goshu GM, Koçak N, Xie E, Silverman RB, Özdinler PH. Improving mitochondria and ER stability helps eliminate upper motor neuron degeneration that occurs due to mSOD1 toxicity and TDP-43 pathology. Clin Transl Med 2021;11:e336. [PMID: 33634973 DOI: 10.1002/ctm2.336] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]